Quantcast
Last updated on April 23, 2014 at 17:36 EDT

Latest OriGene Technologies Inc. Stories

2014-02-26 23:01:13

OriGene Technologies, Inc. (“OriGene”), one of the industry leaders in producing genome wide products for research and diagnostic applications, announced today that it has acquired BioCheck, Inc. (“BioCheck”), a provider of innovative immunodiagnostic test kits and custom immunoassay development for the world-wide health care and research markets. Rockville, MD (PRWEB) February 26, 2014 The acquisition of BioCheck expands OriGene’s IVD portfolio and capabilities for future...

2014-01-31 23:24:23

OriGene Technologies, Inc. (“OriGene”), one of the industry leaders in producing genome wide products for research and diagnostic applications, has been awarded a contract from the National Cancer Institute (NCI) to develop high affinity anti-peptide antibodies for SISCAPA assays. Rockville, MD (PRWEB) January 31, 2014 Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA), an approach developed by Dr. Leigh Anderson, is a novel technology that can achieve high...

2013-11-21 23:33:32

OriGene, a privately held biotech company, was selected as one of fastest growing technology companies in North America. Rockville, Maryland (PRWEB) November 21, 2013 OriGene, a privately held biotech company, was selected as one of fastest growing technology companies in North America. On Nov 13th, Deloitte released the 2013 Technology Fast 500™, an annual ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North...

2013-04-08 12:27:53

ROCKVILLE, Md., April 8, 2013 /PRNewswire/ -- OriGene Technologies, Inc., a leading genome wide product company for research and diagnostic applications with operations in the United States and China, announced that it has signed a definitive agreement to acquire all the assets of the Life Science business of SDIX(TM) (NASDAQ: SDIX), a leading provider of biotechnology-based products and services. (Logo: http://photos.prnewswire.com/prnh/20130408/DC90285LOGO) "We anticipate the...

2013-03-21 12:27:50

ROCKVILLE, Md., March 21, 2013 /PRNewswire/ -- OriGene Technologies, Inc., a leading genome wide product company for research and diagnostic applications, announced the completion of a $21.3 million Series C financing led by Qiming Venture Partners and Kleiner Perkins Caufield Byers China. OriGene's previous investor IDG-Accel also participated in this round. "We are pleased with the high level of commitment and enthusiasm from our new and existing investors. We intend to use the net...

2013-01-07 12:25:55

ROCKVILLE, Md., Jan. 7, 2013 /PRNewswire/ -- OriGene Technologies, Inc. ("OriGene"), one of the industry leaders in producing genome wide products for research and diagnostic applications, has brought the antibody field one step closer to identifying and developing ultra-specific monoclonal antibodies. Specificity of antibodies for research or clinical applications is of critical importance and therefore it is a "must" to demonstrate antibody specificity with high...

2012-07-19 14:21:27

ROCKVILLE, Md., July 19, 2012 /PRNewswire/ -- OriGene Technologies, Inc. and Canada's Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) today announced the selection of OriGene Technologies as a major collaboration and development partner to implement blood-based protein assays in heart and kidney transplantation. This multi-year, collaborative project funded by multiple partners will provide monitoring and predictive blood tests, based upon OriGene's extensive expertise...

2012-03-20 06:26:05

ROCKVILLE, Md., March 20, 2012 /PRNewswire/ -- OriGene Technologies today announced the release of a new line of ultra specific and extensively validated monoclonal antibodies under the UltraMAB(TM) brand. UltraMAB Antibodies are a collection of monoclonal antibodies which are exclusively developed by OriGene for IHC applications and are the industry's only antibody products available on the market that have been validated with the Company's breakthrough 10K High Density Protein Microarray...

2012-03-12 13:00:00

ROCKVILLE, Md., March 12, 2012 /PRNewswire/ -- OriGene Technologies, Inc. announces the acquisition of Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd (ZsBio). The strategic acquisition establishes OriGene's leading position in the Chinese pathology testing market. Headquartered in Beijing, China since 1993, ZsBio provides pathology testing products to the growing Chinese oncology diagnostic market. ZsBio has an industry leading position in the Chinese pathology testing...

2011-07-28 09:29:00

3000 Highly Validated Monoclonal Antibodies Made Against Native Protein Epitopes Expands OriGene's Antibody Portfolio to Over 7500 ROCKVILLE, Md., July 28, 2011 /PRNewswire-USNewswire/ -- OriGene Technologies, Inc. a gene-centric life sciences company, today announced that through its July release, the TrueMAB(TM) monoclonal antibodies have reached the 3000 product milestone. Each TrueMAB, made against antigens produced mostly in HEK293T cells, has proven superior in performance for...